Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above 200 Day Moving Average – Should You Sell?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.39 and traded as high as $1.50. Atossa Therapeutics shares last traded at $1.50, with a volume of 362,114 shares traded.

Analyst Ratings Changes

Several research analysts have recently commented on ATOS shares. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Atossa Therapeutics in a report on Monday, August 12th. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Finally, Ascendiant Capital Markets upped their target price on Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research note on Wednesday, September 11th.

Atossa Therapeutics Price Performance

The firm has a market cap of $188.64 million, a PE ratio of -6.25 and a beta of 1.20. The company has a 50 day simple moving average of $1.41 and a 200-day simple moving average of $1.39.

Atossa Therapeutics (NASDAQ:ATOS) last issued its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, sell-side analysts predict that Atossa Therapeutics, Inc. will post -0.22 EPS for the current fiscal year.

Institutional Trading of Atossa Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its position in Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the last quarter. Cetera Advisors LLC bought a new stake in Atossa Therapeutics in the first quarter valued at approximately $72,000. Virtu Financial LLC bought a new stake in Atossa Therapeutics in the first quarter valued at approximately $151,000. Rhumbline Advisers bought a new stake in Atossa Therapeutics in the second quarter valued at approximately $161,000. Finally, Vanguard Group Inc. lifted its position in Atossa Therapeutics by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after purchasing an additional 78,269 shares during the last quarter. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.